Partners and Collaborators

Santaris Pharma A/S rapidly becoming the partner of-choice in developing RNA-targeted therapies

Santaris Pharma A/S is rapidly becoming the preferred partner for the development of RNA-targeted medicines having established partnerships with four pharmaceutical companies over the past four years. These partnerships further validate the broad utility of the Santaris Pharma A/S LNA Drug Platform and Drug Discovery Engine to develop effective and well tolerated LNA-based drugs across multiple disease areas for its partners.

Partnerships are a critical element of the Company's strategy to leverage its LNA Drug Platform and Drug Discovery Engine to deliver on the promise of RNA-targeted drugs, today.

Key elements of the existing partnerships include:

  • Exclusivity on targets, not therapeutic areas
  • Design and selection from optimal drug candidates
  • Shared responsibility for further development (pharmacology, toxicology, late stage preclinical and clinical)
  • Access and exclusivity research FTEs and downstream milestones and royalties

Delivering RNA-targeted drugs to partners and collaborators, today

  • Four major partnerships in last four years
  • Partnerships to date that cover more than 25 different potential targets, residing in many different tissues and involved in a diversity of diseases, including infectious and inflammatory diseases, metabolic disorders, cancer and rare genetic disorders.
  • Delivered drug candidates against 10 different targets
  • Two partnered programs currently in clinical development